BioCentury
ARTICLE | Clinical News

Axsome's AXS-05 meets in Phase II for smoking cessation

April 25, 2019 9:50 PM UTC

Axsome said twice-daily AXS-05 met the primary endpoint of reducing the mean number of cigarettes smoked per day assessed over a 3-week period vs. bupropion in a Phase II trial for smoking cessation (8.49 vs. 6.79 cigarettes per day, p=0.0016).

AXS-05 comprises dextromethorphan, an NMDA receptor antagonist, σ-1 receptor agonist and inhibitor of serotonin and norepinephrine transporters, plus bupropion, a norepinephrine and dopamine reuptake inhibitor and nicotinic acetylcholine receptor (nAchR) antagonist...